Impact of Cytomegalovirus (CMV) Reactivation after Umbilical Cord Blood Transplantation

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 2, 2010, Pages 215-222

  Beck, Jill C ^a   Wagner, John E ^a   DeFor, Todd E ^a   Brunstein, Claudio G ^a   Schleiss, Mark R ^a   Young, Jo Anne ^a   Weisdorf, Daniel H ^a   Cooley, Sarah ^a   Miller, Jeffrey S ^a   Verneris, Michael R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Cord blood transplantation; Cytomegalovirus; GVHD; Prophylaxis

Indexed keywords

CD3 ANTIGEN; CD34 ANTIGEN; HLA ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ARTICLE; CANCER RELAPSE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; FEMALE; GRAFT RECIPIENT; HAPLOTYPE; HEMATOLOGIC MALIGNANCY; HUMAN; INFANT; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PREDICTION; PRESCHOOL CHILD; RISK FACTOR; SCHOOL CHILD; SEROTYPE; TREATMENT OUTCOME; VIRUS REACTIVATION;

ACUTE DISEASE; AGING; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; INCIDENCE; MALE; RECURRENCE; RISK FACTORS; SEROLOGIC TESTS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 75149121841     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.09.019     Document Type: Article

References (51)

1. Barker J.N., and Wagner J.E. Umbilical-cord blood transplantation for the treatment of cancer. Nat Rev Cancer 3 (2003) 526-532
2. Harris D.T., Schumacher M.J., Locasio J., et al. Phenotypic and functional immaturity of human umbilical cord blood T lymphocytes. Proc Natl Acad Sci USA 89 (1992) 10006-10010
3. Matsumura T., Narimatsu H., Kami M., et al. Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients. Biol Blood Marrow Transplant 13 (2007) 577-583
4. Barker J.N., Hough R.E., van Burik J.A., et al. Serious infections after unrelated donor transplantation in 136 children: impact of stem cell source. Biol Blood Marrow Transplant 11 (2005) 362-370
5. Szabolcs P., and Niedzwiecki D. Immune reconstitution after unrelated cord blood transplantation. Cytotherapy 9 (2007) 111-122
6. Rocha V., Cornish J., Sievers E.L., et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 97 (2001) 2962-2971
7. Martin P.J., Komanduri K.V., St. John L.S., et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 110 (2007) 4543-4551
8. Nakamura R., Battiwalla M., Solomon S., et al. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. Biol Blood Marrow Transplant 10 (2004) 49-57
9. Nichols W.G., Corey L., Gooley T., et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 185 (2002) 273-282
10. Boeckh M., Nichols W.G., Papanicolaou G., et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant 9 (2003) 543-558
11. Walker C.M., van Burik J.A., De For T.E., et al. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources. Biol Blood Marrow Transplant 13 (2007) 1106-1115
12. Castagnola E., Capelli B., Erba D., et al. Cytomegalovirus infection after bone marrow transplantation in children. Hum Immunol 65 (2004) 416-422
13. Osarogiagbon R.U., Defor T.E., Weisdorf M.A., et al. CMV antigenemia following bone marrow transplantation: risk factors and outcomes. Biol Blood Marrow Transplant 6 (2000) 280-288
14. Montesinos P., Sanz J., Cantero S., et al. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. Biol Blood Marrow Transplant 15 (2009) 730-740
15. Zaia J.A. Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect Dis 35 (2002) 999-1004
16. Nakamae H., Kirby K.A., Sandmaier B.M., et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 15 (2009) 694-703
17. Albano M.S., Taylor P., Pass R.F., et al. Umbilical cord blood transplantation and cytomegalovirus: posttransplantation infection and donor screening. Blood 108 (2006) 4275-4282
18. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100 (2002) 1611-1618
19. Bachanova V., Verneris M.R., DeFor T., Brunstein C.G., and Weisdorf D.J. Prolonged survival in adults with acute lymphoblastic leukemia (ALL) following reduced intensity conditioning with cord blood or sibling donor transplantation. Blood 113 (2009) 2902-2905
20. MacMillan M.L., Weisdorf D.J., Brunstein C.G., et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood 113 (2009) 2410-2415
21. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
22. Ljungman P., Griffiths P., and Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34 (2002) 1094-1097
23. Cooley S., Trachtenberg E., Bergemann T.L., et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 113 (2009) 726-732
24. Lin D.Y. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 168 (1997) 901-910
25. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
26. Cox D.R. Regression models and life tables. J R Stat Soc 34 (1972) 187-220
27. Kurtzberg J., Prasad V.K., Carter S.L., et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 112 (2008) 4318-4327
28. Broers A.E., van der H.R., van Esser J.W.J., et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 95 (2000) 2240-2245
29. Meyers J.D., Flournoy N., and Thomas E.D. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 153 (1986) 478-488
30. Zaia J.A., and Forman S.J. Cytomegalovirus infection in the bone marrow transplant recipient. Infect Dis Clin N Am 9 (1995) 879-900
31. Takami A., Mochizuki K., Asakura H., et al. High incidence of cytomegalovirus reactivation in adult recipients of an unrelated cord blood transplant. Haematologica 90 (2005) 1290-1292
32. Bordon V., Bravo S., Van Renterghemet L., et al. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease. Transpl Infect Dis 10 (2008) 19-23
33. Parody R., Martino R., Rovira M., et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant 12 (2006) 734-748
34. Junghanss C., Boeckh M., Carter R.A., et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 99 (2002) 1978-1985
35. Tomonari A., Iseki T., Ooi J J., et al. Cytomegalovirus infection following unrelated cord blood transplantation for adult patients: a single institute experience in Japan. Br J Haematol 121 (2003) 304-311
36. Tomonari A., Takahashi S., Ooiet J., et al. Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan. Eur J Haematol 80 (2008) 251-257
37. Nachbaur D., Clausen J., and Kircher B. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants. Eur J Haematol 76 (2006) 414-419
38. Ozdemir E., St. John L.S., Gillespie G., et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 40 (2007) 125-136
39. Burns L.J., Miller W., Kandaswamyet C., et al. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Bone Marrow Transplant 30 (2002) 945-951
40. Boeckh M., Leisenring W., Riddell S.R., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101 (2003) 407-414
41. Behrendt C.E., Rosenthal J., Bolotin E., Nakamura R., Zaia J., and Forman S.J. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplant 15 (2009) 54-60
42. Ishaqi M.K., Afzal S., Dupuis A., Doyle J., and Gassas A. Early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation is associated with significant graft-versus-leukemia effect without increase in graft-versus-host disease in pediatric acute lymphoblastic leukemia. Bone Marrow Transplant 41 (2008) 245-252
43. Kumar S., Chen M.G., Gastineau D.A., et al. Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia. Leukemia 17 (2003) 1865-1870
44. Savani B.N., Mielke S., Rezvani K., et al. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant 13 (2007) 1216-1223
45. Hiwase D.K., Hiwase S., Bailey M., Bollard G., and Schwarer A.P. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 14 (2008) 116-124
46. Kumar S., Chen M.G., Gastineau d., et al. Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 28 (2001) 951-956
47. Porrata L.F., Inwards D.J., Micallef I.N., et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 98 (2001) 579-585
48. Porrata L.F., Gertz M.A., Litzow M.R., et al. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant 14 (2008) 807-816
49. Uhrberg M., Valiante NM N.M., Shum B.P., et al. Human diversity in killer cell inhibitory receptor genes. Immunity 7 (1997) 753-763
50. Cook M., Briggs D., Craddock C., et al. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood 107 (2006) 1230-1232
51. Zaia J.A., Sun J.Y., Gallez-Hawkins G.M., et al. The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation. Biol Blood Marrow Transplant 15 (2009) 315-325